5-HT2A receptor density is decreased in the at-risk mental state
Rationale Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS). Objective To study the cerebral 5-HT 2A receptor (5-HT 2A R) in the ARMS with [ 18 F]altanserin positron emission to...
Gespeichert in:
Veröffentlicht in: | Psychopharmacologia 2008-01, Vol.195 (4), p.579-590 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 590 |
---|---|
container_issue | 4 |
container_start_page | 579 |
container_title | Psychopharmacologia |
container_volume | 195 |
creator | Hurlemann, René Matusch, Andreas Kuhn, Kai-Uwe Berning, Julia Elmenhorst, David Winz, Oliver Kolsch, Heike Zilles, Karl Wagner, Michael Maier, Wolfgang Bauer, Andreas |
description | Rationale
Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS).
Objective
To study the cerebral 5-HT
2A
receptor (5-HT
2A
R) in the ARMS with [
18
F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm.
Materials and methods
We quantified the spatial distribution of 5-HT
2A
R binding potential (BP
1
′) in never-medicated subjects assigned to early (
n
= 6) and late (
n
= 8) prodromal states of schizophrenia relative to healthy controls (
n
= 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT
2A
R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP
1
′ due to between-group differences in genotype distributions.
Results
Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP
1
′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP
1
′ was present in subjects who subsequently converted to first-episode psychosis (
n
= 5), but absent in non-converters (
n
= 9). Between-group differences were not confounded by a differential distribution of SNP genotypes.
Conclusion
These results suggest a progressive reduction of cortical 5-HT
2A
R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT
2A
R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia. |
doi_str_mv | 10.1007/s00213-007-0921-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70099863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70099863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</originalsourceid><addsrcrecordid>eNp1kMtKBDEQRYMoOj4-wI00gu6ieXYnO0V8geBG1yHJVGtrT_eYyoD-vRlmYEAwm9yizq0qLiHHnF1wxppLZExwSYukzApOv7fIhCspqGCN2CYTxqSkkmuzR_YRP1h5yqhdsscbY23xTsiVpg8v4rpKEGGex1RNYcAu_1QdFhkTeIRp1Q1VfofKZ5o6_KxmMGTfV5h9hkOy0_oe4Wj9H5DXu9uXmwf69Hz_eHP9RKOqdaZKBW1aJWIMtRbT1sQopNE6RO2FbxoNNjRBBq9VlEbF2stSKKFE8EGClwfkfDV3nsavBWB2sw4j9L0fYFygaxiz1tSygKd_wI9xkYZymxPc2IbXhhWIr6CYRsQErZunbubTj-PMLbN1q2zdUi6zdd_Fc7IevAgzmG4c6zALcLYGPEbft8kPscMNZ62qlV4uFysOS2t4g7S58P_tvwiWj9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218971680</pqid></control><display><type>article</type><title>5-HT2A receptor density is decreased in the at-risk mental state</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Hurlemann, René ; Matusch, Andreas ; Kuhn, Kai-Uwe ; Berning, Julia ; Elmenhorst, David ; Winz, Oliver ; Kolsch, Heike ; Zilles, Karl ; Wagner, Michael ; Maier, Wolfgang ; Bauer, Andreas</creator><creatorcontrib>Hurlemann, René ; Matusch, Andreas ; Kuhn, Kai-Uwe ; Berning, Julia ; Elmenhorst, David ; Winz, Oliver ; Kolsch, Heike ; Zilles, Karl ; Wagner, Michael ; Maier, Wolfgang ; Bauer, Andreas</creatorcontrib><description>Rationale
Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS).
Objective
To study the cerebral 5-HT
2A
receptor (5-HT
2A
R) in the ARMS with [
18
F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm.
Materials and methods
We quantified the spatial distribution of 5-HT
2A
R binding potential (BP
1
′) in never-medicated subjects assigned to early (
n
= 6) and late (
n
= 8) prodromal states of schizophrenia relative to healthy controls (
n
= 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT
2A
R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP
1
′ due to between-group differences in genotype distributions.
Results
Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP
1
′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP
1
′ was present in subjects who subsequently converted to first-episode psychosis (
n
= 5), but absent in non-converters (
n
= 9). Between-group differences were not confounded by a differential distribution of SNP genotypes.
Conclusion
These results suggest a progressive reduction of cortical 5-HT
2A
R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT
2A
R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-007-0921-x</identifier><identifier>PMID: 17899021</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Adult and adolescent clinical studies ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Brain - diagnostic imaging ; Brain Mapping ; Cerebral Cortex - diagnostic imaging ; Dominance, Cerebral - physiology ; Early Diagnosis ; Female ; Fluorine Radioisotopes ; Genetic Markers - genetics ; Genetic Predisposition to Disease ; Genotype ; Genotype & phenotype ; Humans ; Ketanserin - analogs & derivatives ; Male ; Medical sciences ; Neurosciences ; Neurotransmitters ; Original Investigation ; Pharmacology ; Pharmacology/Toxicology ; Positron-Emission Tomography ; Psychiatric Status Rating Scales ; Psychiatry ; Psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Receptor, Serotonin, 5-HT2A - genetics ; Risk factors ; Schizophrenia ; Schizophrenia - diagnostic imaging ; Schizophrenia - genetics ; Schizotypal Personality Disorder - diagnostic imaging ; Schizotypal Personality Disorder - genetics</subject><ispartof>Psychopharmacologia, 2008-01, Vol.195 (4), p.579-590</ispartof><rights>Springer-Verlag 2007</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</citedby><cites>FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-007-0921-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-007-0921-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19946450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17899021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hurlemann, René</creatorcontrib><creatorcontrib>Matusch, Andreas</creatorcontrib><creatorcontrib>Kuhn, Kai-Uwe</creatorcontrib><creatorcontrib>Berning, Julia</creatorcontrib><creatorcontrib>Elmenhorst, David</creatorcontrib><creatorcontrib>Winz, Oliver</creatorcontrib><creatorcontrib>Kolsch, Heike</creatorcontrib><creatorcontrib>Zilles, Karl</creatorcontrib><creatorcontrib>Wagner, Michael</creatorcontrib><creatorcontrib>Maier, Wolfgang</creatorcontrib><creatorcontrib>Bauer, Andreas</creatorcontrib><title>5-HT2A receptor density is decreased in the at-risk mental state</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale
Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS).
Objective
To study the cerebral 5-HT
2A
receptor (5-HT
2A
R) in the ARMS with [
18
F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm.
Materials and methods
We quantified the spatial distribution of 5-HT
2A
R binding potential (BP
1
′) in never-medicated subjects assigned to early (
n
= 6) and late (
n
= 8) prodromal states of schizophrenia relative to healthy controls (
n
= 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT
2A
R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP
1
′ due to between-group differences in genotype distributions.
Results
Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP
1
′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP
1
′ was present in subjects who subsequently converted to first-episode psychosis (
n
= 5), but absent in non-converters (
n
= 9). Between-group differences were not confounded by a differential distribution of SNP genotypes.
Conclusion
These results suggest a progressive reduction of cortical 5-HT
2A
R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT
2A
R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain - diagnostic imaging</subject><subject>Brain Mapping</subject><subject>Cerebral Cortex - diagnostic imaging</subject><subject>Dominance, Cerebral - physiology</subject><subject>Early Diagnosis</subject><subject>Female</subject><subject>Fluorine Radioisotopes</subject><subject>Genetic Markers - genetics</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Humans</subject><subject>Ketanserin - analogs & derivatives</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurosciences</subject><subject>Neurotransmitters</subject><subject>Original Investigation</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Positron-Emission Tomography</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Receptor, Serotonin, 5-HT2A - genetics</subject><subject>Risk factors</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnostic imaging</subject><subject>Schizophrenia - genetics</subject><subject>Schizotypal Personality Disorder - diagnostic imaging</subject><subject>Schizotypal Personality Disorder - genetics</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kMtKBDEQRYMoOj4-wI00gu6ieXYnO0V8geBG1yHJVGtrT_eYyoD-vRlmYEAwm9yizq0qLiHHnF1wxppLZExwSYukzApOv7fIhCspqGCN2CYTxqSkkmuzR_YRP1h5yqhdsscbY23xTsiVpg8v4rpKEGGex1RNYcAu_1QdFhkTeIRp1Q1VfofKZ5o6_KxmMGTfV5h9hkOy0_oe4Wj9H5DXu9uXmwf69Hz_eHP9RKOqdaZKBW1aJWIMtRbT1sQopNE6RO2FbxoNNjRBBq9VlEbF2stSKKFE8EGClwfkfDV3nsavBWB2sw4j9L0fYFygaxiz1tSygKd_wI9xkYZymxPc2IbXhhWIr6CYRsQErZunbubTj-PMLbN1q2zdUi6zdd_Fc7IevAgzmG4c6zALcLYGPEbft8kPscMNZ62qlV4uFysOS2t4g7S58P_tvwiWj9Q</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Hurlemann, René</creator><creator>Matusch, Andreas</creator><creator>Kuhn, Kai-Uwe</creator><creator>Berning, Julia</creator><creator>Elmenhorst, David</creator><creator>Winz, Oliver</creator><creator>Kolsch, Heike</creator><creator>Zilles, Karl</creator><creator>Wagner, Michael</creator><creator>Maier, Wolfgang</creator><creator>Bauer, Andreas</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>5-HT2A receptor density is decreased in the at-risk mental state</title><author>Hurlemann, René ; Matusch, Andreas ; Kuhn, Kai-Uwe ; Berning, Julia ; Elmenhorst, David ; Winz, Oliver ; Kolsch, Heike ; Zilles, Karl ; Wagner, Michael ; Maier, Wolfgang ; Bauer, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain - diagnostic imaging</topic><topic>Brain Mapping</topic><topic>Cerebral Cortex - diagnostic imaging</topic><topic>Dominance, Cerebral - physiology</topic><topic>Early Diagnosis</topic><topic>Female</topic><topic>Fluorine Radioisotopes</topic><topic>Genetic Markers - genetics</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Humans</topic><topic>Ketanserin - analogs & derivatives</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurosciences</topic><topic>Neurotransmitters</topic><topic>Original Investigation</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Positron-Emission Tomography</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Receptor, Serotonin, 5-HT2A - genetics</topic><topic>Risk factors</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnostic imaging</topic><topic>Schizophrenia - genetics</topic><topic>Schizotypal Personality Disorder - diagnostic imaging</topic><topic>Schizotypal Personality Disorder - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hurlemann, René</creatorcontrib><creatorcontrib>Matusch, Andreas</creatorcontrib><creatorcontrib>Kuhn, Kai-Uwe</creatorcontrib><creatorcontrib>Berning, Julia</creatorcontrib><creatorcontrib>Elmenhorst, David</creatorcontrib><creatorcontrib>Winz, Oliver</creatorcontrib><creatorcontrib>Kolsch, Heike</creatorcontrib><creatorcontrib>Zilles, Karl</creatorcontrib><creatorcontrib>Wagner, Michael</creatorcontrib><creatorcontrib>Maier, Wolfgang</creatorcontrib><creatorcontrib>Bauer, Andreas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hurlemann, René</au><au>Matusch, Andreas</au><au>Kuhn, Kai-Uwe</au><au>Berning, Julia</au><au>Elmenhorst, David</au><au>Winz, Oliver</au><au>Kolsch, Heike</au><au>Zilles, Karl</au><au>Wagner, Michael</au><au>Maier, Wolfgang</au><au>Bauer, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5-HT2A receptor density is decreased in the at-risk mental state</atitle><jtitle>Psychopharmacologia</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>195</volume><issue>4</issue><spage>579</spage><epage>590</epage><pages>579-590</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>Rationale
Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS).
Objective
To study the cerebral 5-HT
2A
receptor (5-HT
2A
R) in the ARMS with [
18
F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm.
Materials and methods
We quantified the spatial distribution of 5-HT
2A
R binding potential (BP
1
′) in never-medicated subjects assigned to early (
n
= 6) and late (
n
= 8) prodromal states of schizophrenia relative to healthy controls (
n
= 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT
2A
R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP
1
′ due to between-group differences in genotype distributions.
Results
Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP
1
′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP
1
′ was present in subjects who subsequently converted to first-episode psychosis (
n
= 5), but absent in non-converters (
n
= 9). Between-group differences were not confounded by a differential distribution of SNP genotypes.
Conclusion
These results suggest a progressive reduction of cortical 5-HT
2A
R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT
2A
R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>17899021</pmid><doi>10.1007/s00213-007-0921-x</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-3158 |
ispartof | Psychopharmacologia, 2008-01, Vol.195 (4), p.579-590 |
issn | 0033-3158 1432-2072 |
language | eng |
recordid | cdi_proquest_miscellaneous_70099863 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Adult Adult and adolescent clinical studies Biological and medical sciences Biomedical and Life Sciences Biomedicine Brain - diagnostic imaging Brain Mapping Cerebral Cortex - diagnostic imaging Dominance, Cerebral - physiology Early Diagnosis Female Fluorine Radioisotopes Genetic Markers - genetics Genetic Predisposition to Disease Genotype Genotype & phenotype Humans Ketanserin - analogs & derivatives Male Medical sciences Neurosciences Neurotransmitters Original Investigation Pharmacology Pharmacology/Toxicology Positron-Emission Tomography Psychiatric Status Rating Scales Psychiatry Psychology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Receptor, Serotonin, 5-HT2A - genetics Risk factors Schizophrenia Schizophrenia - diagnostic imaging Schizophrenia - genetics Schizotypal Personality Disorder - diagnostic imaging Schizotypal Personality Disorder - genetics |
title | 5-HT2A receptor density is decreased in the at-risk mental state |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A21%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5-HT2A%20receptor%20density%20is%20decreased%20in%20the%20at-risk%20mental%20state&rft.jtitle=Psychopharmacologia&rft.au=Hurlemann,%20Ren%C3%A9&rft.date=2008-01-01&rft.volume=195&rft.issue=4&rft.spage=579&rft.epage=590&rft.pages=579-590&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/s00213-007-0921-x&rft_dat=%3Cproquest_cross%3E70099863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218971680&rft_id=info:pmid/17899021&rfr_iscdi=true |